Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma: The New Standard of Care? Miura JT, Karakousis GC. Ann Surg Oncol 2024 Dec 29. doi: 10.1245/s10434-024-16807.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Miura JT, Karakousis GC. Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma: The New Standard of Care? Ann Surg Oncol 2024 Dec 29. doi: 10.1245/s10434-024-16807.
PMID: 39739267